Takeda CEO Tells Reuters The Co. Will Raise Innovation Bar For R&D Projects After Shire Merger, Will Consider Biotech Spin-Offs For Pipeline Drugs That Are Dropped; Says Discussions Are Starting For Finding Long-Term Strategic Investors For The Co.